Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

The Journal of Clinical Pharmacology(2021)10.1002/jcph.1984Source: DataRank Database

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation is a research paper published in The Journal of Clinical Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access35 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (19)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Brian L. Heiss ORCID,Daniel A. Goldstein ORCID,Jennifer C. Goodell,William D. Figg ORCID,Mark J. Ratain ORCID

Live enrichment

PubMed:34648187 PMC:PMC9749861

Intramural NIH HHS

Grant: Z01 SC006537

NIGMS NIH HHS

Grant: T32 GM007019

NIAID NIH HHS

Grant: T32 AI007019

Intramural NIH HHS

Grant: ZIC SC006537

greenLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9749861

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1984

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/jcph.1984

publisherhttps://accp1.onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1984

Fields of Study

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalComputer SimulationDose-Response Relationship, DrugHumansNivolumabProspective Studies

MeSH Terms

HumansProspective StudiesDose-Response Relationship, DrugComputer SimulationAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalNivolumab

Keywords

ImmunopharmacologyOncologyClinical Trialsmodeling and simulationPopulation Pharmacokinetics

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

FAIR Checklist

Authors (6)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)